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ABSTRACT
Purpose. Hepatocellular carcinoma (HCC) is an in-
creasing cause of mortality in HIV-infected patients in
the highly active antiretroviral therapy (HAART) era.
The aims of this study were to describe HCC tumor
characteristics and different therapeutic approaches, to
evaluate patient survival time from HCC diagnosis, and
to identify clinical prognostic predictors in patients with
and without HIV infection.
Patients and Methods. A multicenter observational
retrospective comparison of 104 HIV-infected patients
and 484 uninfected patients was performed in four Ital-
ian centers. HCC was staged according to the Barcelona
Clinic Liver Cancer (BCLC) criteria.
Results. Tumor characteristics of patients with and
without HIV were significantly different for age, East-
ern Cooperative Oncology Group performance status
(PS) score<1, and etiology of chronic liver disease. De-
spite the similar potentially curative option rate and
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